KEY POINTS:
Wakefield Health yesterday reported profit after tax from continuing operations of $6.13 million for the six months ended September 30, up 35.8 per cent on last year.
Net profit after tax was up 63.2 per cent but the previous year included a large loss from the disposal of an investment in P3 Research. The company declared an interim dividend of 10c a share, payable on December 5.
Solid growth was maintained across each of its three hospitals but the company said it could not predict demand for private hospital services in the current economic environment.
Elective surgery performed under contract from District Health Boards had added to the use of company facilities, but it was unpredictable in its extent and timing.
The company entered into a contract with the Capital and Coast District Health Board last month to complete 30 cardiac operations before December 24, and has received indications of a likely further contract for a similar number in the first quarter.
The company is commissioning its seventh operating theatre at Wakefield Hospital with full digital capability, as well as retro-fitting another.
It is looking at opportunities in the Auckland region but is taking a cautious approach.
- NZPA
